Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials
Pharmaceutics · 03.05.2025 · 17 (5) · 608
DOI: 10.3390/pharmaceutics17050608 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 03.05.2025. Verfasst von Matteo Gallina und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), School of Specialization in Hospital Pharmacy, University…. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, Rome, Italy (Ricerca Corrente).
Abstract (Originalsprache)
Background/Objectives: Lung cancer is the leading cause of cancer-related deaths worldwide. Non-Small-Cell Lung Cancer (NSCLC) accounts for 80–90% of all lung cancers. Antibody-Drug Conjugates (ADCs) represent an expanding targeted therapy option for the treatment of NSCLC. The aim is to perform a systematic literature review to evaluate the efficacy and safety profiles of ADCs currently undergoing clinical trials for the treatment of NSCLC.
Methods
The study adhered to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement. Literature searches were conducted in PubMed, ClinicalTrial.gov and Web of Science databases, covering the period from 2014 to 2024. Only randomized and non-randomized phase II-IV clinical trials focusing on ADC-based therapies for adult patients affected by NSCLC were selected. The Revised Cochrane Risk-of-Bias Tool for Randomized Trials (RoB 2.0) and the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) were used to evaluate the overall risk of bias in the included randomized and non-randomized studies, respectively. While GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology was used to assess the certainty of the evidence. Efficacy endpoints were categorized based on primary outcomes while safety was assessed through the frequency and severity of Treatment-Emergent Adverse Events (TEAEs), and a qualitative summary of the findings was conducted.
Results
A total of seven studies, including three randomized, three non-randomized, and one without specific allocation, were included, comprising 1287 patients, with 693 (54%) men, and an average age of 63 years old. Two studies were deemed to have a low risk of bias, while six had a moderate risk or some concerns. Five ADCs were evaluated: trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1), telisotuzumab vedotin, patritumab deruxtecan, and datopotamab deruxtecan (Dato-DXd). T-DXd demonstrated superior efficacy in HER2-overexpressing and HER2-mutant NSCLC, with an ORR of 52.9% and 49.0%, respectively. However, HER2-mutant patients exhibited a longer median DOR (16.8 vs. 6.2 months) but a higher incidence of grade ≥ 3 TEAEs (38.6% vs. 22%). T-DM1 showed modest efficacy, with an ORR of 20% in HER2-overexpressing NSCLC and 6.7% in HER2-mutant patients. Dato-DXd demonstrated improved ORR (26.4% vs. 12.8%) and PFS (4.4 vs. 3.7 months) compared to docetaxel. Patritumab deruxtecan achieved an ORR of 39% in EGFR-mutant NSCLC, while telisotuzumab vedotin exhibited limited activity in c-MET-positive NSCLC (ORR 9%, median DOR 7.5 months). Frequency and severity of TEAEs varied across ADCs, with ILD being a major concern, highlighting the need for strict patient monitoring and early intervention to mitigate severe adverse events.
Conclusions
ADCs represent a promising advancement in NSCLC treatment, offering targeted therapeutic options beyond conventional chemotherapy and immunotherapy. T-DXd has emerged as the most effective ADC for HER2-mutant NSCLC with manageable safety profile, whereas Dato-DXd provides a viable alternative for TROP2-expressing tumors. While ADCs offer significant clinical benefits, careful patient selection and proactive management of adverse events remain crucial. Ongoing and future trials will further refine the role of ADCs in personalized NSCLC treatment, potentially expanding their tumor-agnostic use to broader patient populations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), School of Specialization in Hospital Pharmacy, University of Palermo, Viale delle Scienze, Ed.16-17, 90128 Palermo, Italy.
- Clinical Pharmacy Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Via Ernesto Tricomi, 5, 90127 Palermo, Italy.
- Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, School of Specialization in Hospital Pharmacy, University of Messina, Viale Ferdinando Stagno d'Alcontres, 31, 98166 Messina, Italy.
- Medical Oncology Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Via Ernesto Tricomi, 5, 90127 Palermo, Italy.
ORCID-Profile: Matteo Gallina, Anna Carollo, Sofia Cutaia, Alessio Provenzani
Förderung
- Italian Ministry of Health, Rome, Italy (Ricerca Corrente)
Zitieren
APA
Gallina, M., Carollo, A., Gallina, A., Cutaia, S., Rizzo, S., & Provenzani, A. (2025). Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials. Pharmaceutics, 17(5), 608. https://doi.org/10.3390/pharmaceutics17050608
Vancouver
Gallina M, Carollo A, Gallina A, Cutaia S, Rizzo S, Provenzani A. Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials. Pharmaceutics. 2025;17(5):608. doi:10.3390/pharmaceutics17050608
BibTeX
@article{Gallina2025,
author = {Gallina, Matteo and Carollo, Anna and Gallina, Anna and Cutaia, Sofia and Rizzo, Sergio and Provenzani, Alessio},
title = {Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {5},
pages = {608},
doi = {10.3390/pharmaceutics17050608}
}
EUVIMED